Spots Global Cancer Trial Database for hlx01
Every month we try and update this database with for hlx01 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL | NCT02787239 | B-cell Non Hodg... | HLX01 Rituximab CHOP | 18 Years - 80 Years | Shanghai Henlius Biotech | |
Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL | NCT02787239 | B-cell Non Hodg... | HLX01 Rituximab CHOP | 18 Years - 80 Years | Shanghai Henlius Biotech | |
Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma. | NCT04671420 | CD20-positive F... | HLX01 Mabthera® | 18 Years - | Shanghai Henlius Biotech | |
A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma | NCT02584920 | B-cell Non Hodg... | HLX01 Rituximab | 18 Years - 65 Years | Shanghai Henlius Biotech |